Dimephosphon®
Dimephosphone is taken orally after meals with water.
The course of treatment depends on the nature of the disease and lasts from 3 days to 2 months.
In complex therapy of the following diseases and conditions:
For acute and chronic cerebrovascular accidents, consequences of ischemic and hemorrhagic strokes,
traumatic brain and neurosurgical trauma
for adults, 15 ml (1 tablespoon) 3-4 times a day. The duration of the course is 2-3 weeks, in some cases up to 6 weeks.
During planned neurosurgical operations
15 ml (1 tablespoon) for 5 days before and 2 months after surgery.
For osteochondrosis
adults: 10 ml (1 dessert spoon) 3-4 times a day for 2-3 weeks, improvement is observed on the 8-10th day of treatment.
For multiple sclerosis
adults: 100 mg/kg (45 ml) per day - 15 ml (1 tablespoon) 3 times a day for 10 days in the autumn-spring period monthly.
For chronic nonspecific lung diseases with signs of respiratory and pulmonary heart failure
adults: 15 ml (1 tablespoon) 3-4 times a day. Course - 7-10 days. The use of dimephosphone does not relieve asthma attacks and does not affect the frequency of use of beta-agonist aerosols.
For vegetative-vascular dystonia of the parasympathetic type
adults 15 ml (1 tablespoon) 3 times a day for 2-3 weeks, children over 12 years old 50 mg/kg (10-15 ml) 3 times a day for 3 weeks.
For chronic cerebrovascular insufficiency due to atherosclerosis and hypertension
15 ml (1 tablespoon) 3 times a day for 2-3 weeks.
For migraine
15 ml (1 tablespoon) 3 times a day for 2-3 weeks.
For Meniere's disease
15 ml (1 tablespoon) 3 times a day for 3 weeks.
For respiratory diseases, acidosis, atonic bronchial asthma and hay fever
adults are prescribed 15-25 ml, children are prescribed 15-25 ml, children are prescribed a dose of 75-100 mg/kg: children under 3 years old - 5 ml (1 teaspoon), 3-8 years old - 10 ml (1 dessert spoon), over 8 years old - 15 ml (1 tablespoon) 3 times a day, in severe cases - 4 times a day for 4-5 weeks.
For atonic bronchial asthma in combination with hay fever
prescribed 2-3 weeks before the onset of deterioration and taken throughout the entire flowering period. For dosing, you can use the measuring cup included in the package.
Externally
For infectious-inflammatory-allergic diseases of the skin and mucous membranes
in the form of bandages, turundas and lotions with a solution daily for
3-14 days.
For complex treatment of acne
wipe the skin 3-4 times a day, apply lotions in the evening.
With erysipelas
- lubricate the inflammation area 3 times a day for 3-5 days.
On the area of seams and places where the knitting needles exit
Apply gauze pads soaked in dimephosphone daily for 7-14 days.
For the prevention of radiation mucositis
- gauze wipes soaked in dimephosphone are placed in the projection of the radiation beams 20 minutes before dose exposure.
Dimephosphon 15% 100ml solution for oral and external use
Release form
Oral solution.
Package
100 ml
pharmachologic effect
Dimephosphone improves the regulation of cerebral circulation, normalizes the reactions of cerebral vessels and blood supply to the brain, and improves venous outflow.
In case of cerebrovascular accidents, it relieves vasomotor cephalgia; reduces cardiac and respiratory failure of central origin.
Normalizes the acid-base state during acidosis of various etiologies. Exhibits membrane-stabilizing, anti-inflammatory, immunomodulatory, antihypoxic, antimutagenic and radioprotective effects, inhibits platelet aggregation.
When applied topically, it has an antiseptic effect and increases the protective functions of the skin and mucous membranes.
Indications
Cerebrovascular accidents, neurosurgical surgical trauma of the brain and spinal cord, traumatic brain injury, Meniere's syndrome and disease, autonomic dysfunction, acute and chronic respiratory diseases with subcompensated pulmonary hypertension, bronchospastic variant of bronchial obstruction (chronic bronchitis, bronchial asthma, pulmonary tuberculosis) , acidosis of various etiologies. Atopic bronchial asthma and hay fever in children, infectious-inflammatory-allergic diseases of the skin and mucous membranes.
Contraindications
hypersensitivity,
chronic renal failure grade 2-3,
epileptic seizures.
special instructions
If drowsiness occurs, refrain from driving vehicles and activities that require increased attention and reaction speed.
Compound
Active ingredients: dimethyloxobutylphosphonyl dimethylate 15 g.
Excipients: purified water up to 100 ml.
Directions for use and doses
Orally prescribed in the form of a solution for adults and children, 30 - 50 mg/kg per dose. For cerebrovascular accidents and Meniere's syndrome, it is prescribed 1-4 times for 1-4 weeks.
For planned neurosurgical operations, it is prescribed for 5 days before and 10-14 days after the operation. For traumatic brain injury, the duration of treatment is from 3 weeks to 2 months.
For autonomic dysfunction, respiratory diseases and acidosis, the duration of treatment is 3-4 weeks. For atopic bronchial asthma, children are prescribed for 2-4 weeks.
To prevent exacerbation of hay fever, take for 3 weeks before the expected seasonal deterioration and during the entire flowering of the allergen plant.
The solution is used externally for infectious-inflammatory-allergic diseases of the skin and mucous membranes in the form of bandages, turundas and lotions daily until recovery.
To prevent radiation mucositis, gauze wipes moistened with a solution are placed in the projection of the radiation beams 20 minutes before dose exposure.
Side effects
nausea,
vomit,
heartburn,
diarrhea (if taken orally),
drowsiness (at the beginning of treatment)
Storage conditions
In a cool place, protected from light.
Best before date
3 years.
Dimephosphone
Dimephosphone solution for oral administration 15% 100 ml x1, ATX code: V03AX (Other drugs)
Dosage form
DIMEPHOSPHONE
solution for oral administration 15%: fl. 100 mlreg. No.: LS-002620 dated 12/29/11 - Valid
Release form, composition and packaging
Oral solution 15% 1 l
dimethyloxobutylphosphonyl dimethylate 150 g
100 ml - dark glass bottles (1) - cardboard packs.
Clinical-pharmacological group: Drug for correction of acid-base balance Pharmaco-therapeutic group: Anti-acidemic drug The scientific information provided is general and cannot be used to make a decision about the possibility of using a specific drug.
Pharmacological action Antiacidemic agent, normalizes the acid-base state in acidosis of various etiologies - by activating the metabolic mechanisms of its regulation (especially renal and pulmonary), increasing intraorgan blood flow and tissue metabolism. It has cerebrovasodilating, nootropic, antidepressant, decongestant, anti-ischemic, stress-protective, mnemotropic and antiamnestic, antiallergic, membrane-stabilizing, immunomodulatory, antihypoxic, antimutagenic and radioprotective effects, suppresses platelet aggregation, stimulates tissue regeneration.
Dose-dependently reduces the intensity of lipid peroxidation, inhibits spontaneous and ADP-induced aggregation, increases the antioxidant activity of platelets and reduces the content of lipid peroxidation products in them.
Improves cerebral circulation, normalizes the tone of cerebral vessels and blood supply to the brain, improves venous outflow. Neurotropic activity and cerebroprotective properties are due to the impact on the mechanisms of neurometabolic protection of the brain (normalizes carbohydrate and energy metabolism, prevents the activation of lipid peroxidation, increases the activity of antioxidant enzymes in brain tissue).
In case of traumatic brain injury, it has a beneficial effect on its metabolism and electrical activity, eliminates vasomotor cephalgia, reduces oxygen consumption by brain tissue, cardiac and respiratory failure of central origin, and promotes regression of focal hemispheric and brain stem symptoms. Eliminates allergic inflammation, in particular, with the development of a leukotriene-dependent reaction of sulfite intolerance, reduces the severity of manifestations of atopic bronchial asthma and atopic dermatitis. In combination with vitamins, pancreatic enzymes and cholestyramine in children with hereditary entero-oxaluric syndrome, it slows down the progression of the disease and increases life expectancy.
When applied topically, it has an antiseptic effect and increases the protective functions of the skin and mucous membranes.
Pharmacokinetics After a single oral dose, it is absorbed quite completely. The time to reach Cmax is 2-2.5 hours. It easily passes through histohematic barriers and is distributed throughout various organs and tissues. The highest concentrations are created in the spleen, brain and red blood cells.
Indications
- acidosis in pneumonia, chronic lung diseases, acute respiratory viral infections, diabetes mellitus and in the postoperative period,
- bronchospastic variant of bronchial obstruction (chronic bronchitis, bronchial asthma, including atopic bronchial asthma in children),
— subcompensated hypertension in the “lesser” circulation,
- hay fever in children,
- transient ischemic attacks, ischemic and hemorrhagic stroke (initial manifestations, consequences of a previous stroke),
— discirculatory encephalopathy (including against the background of arterial hypertension),
- myelopathy, radiculopathy,
– neurosurgical surgical trauma of the brain and spinal cord,
- traumatic brain injury (concussion and brain contusion),
- Meniere's syndrome and disease, autonomic lability,
- atopic dermatitis,
— infectious and inflammatory diseases of the skin and mucous membranes: acne, erysipelas, purulent-inflammatory complications at the exit sites of the Ilizarov apparatus wires,
- ENT and dental diseases,
— mucositis during radiation therapy of malignant neoplasms,
- infected wounds, trophic ulcers,
- rickets-like diseases in children,
- hereditary entero-oxaluric syndrome.
ICD-10 codes
Dosage regimen Orally (children are recommended to drink milk, fruit juice, sweet tea, has a bitter taste), 30-50 mg/kg 1-4 times/day: for cerebrovascular accidents and Meniere's syndrome - for 1-4 weeks, for planned neurosurgical operations - 5 days before and 10-14 days after surgery, for traumatic brain injury - 3-8 weeks, for autonomic dysfunction, respiratory diseases, acidosis, for atopic bronchial asthma (in children) - 2-4 weeks, for prevention of exacerbation of hay fever - 3 weeks before the expected seasonal deterioration and during the entire flowering of the allergen plant.
Externally. For infectious-inflammatory-allergic diseases of the skin and mucous membranes - in the form of bandages, turundas and lotions with a solution daily for 3-14 days, for the prevention of radiation mucositis - gauze wipes moistened with a solution are placed in the projection of the radiation beams 20 minutes before exposure doses.
IV: jet - the contents of 1-2 ampoules are diluted in 10-20 ml of sterile water for injection or 0.9% sodium chloride solution, drip - in 200-400 ml of 0.9% sodium chloride solution. Administer 1-4 times/day for 7-10 days.
Side effects Nausea, vomiting, heartburn, diarrhea (if taken orally), drowsiness (at the beginning of treatment).
Contraindications for use
- hypersensitivity,
— chronic renal failure stage II-III,
- epilepsy.
Use for impaired renal function Contraindicated in chronic renal failure stage II-III.
Special instructions If drowsiness occurs, refrain from driving vehicles and activities that require increased attention and reaction speed.
Drug interactions Strengthens the antiplatelet effect of acetylsalicylic acid.
